Operating CF
$14.31B
Capex
−$5.20B
Free Cash Flow
$9.11B
FCF Margin
+63.7%
Cash flow waterfall for AstraZeneca (AZN) — TTM through Q1 2026
Free cash flow: $9.11B
Cash flow breakdown for AstraZeneca (AZN) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $14.31B | $14.31B |
| Capital Expenditure | −$5.20B | $9.11B |
| Free Cash Flow | $9.11B | $9.11B |
| Acquisitions | −$1.13B | $7.97B |
| Other Investing | −$1.09B | $6.89B |
| Dividends Paid | −$4.89B | $2.00B |
| Net Debt Change | $1.38B | $3.38B |
| Other Financing & FX | −$1.10B | $2.28B |
| Net Cash Increase | $2.28B | $2.28B |
- Operating Cash Flow$14.31B
- Capital Expenditure−$5.20B
- Free Cash Flow$9.11B
- Acquisitions−$1.13B
- Other Investing−$1.09B
- Dividends Paid−$4.89B
- Net Debt Change$1.38B
- Other Financing & FX−$1.10B
- Net Cash Increase$2.28B
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement